161 related articles for article (PubMed ID: 21539486)
1. Management of suspected Alzheimer's disease patients by specialist physicians at the first visit in Spain: First Consultation Study.
Martínez Lozano MD; Guzmán Quilo C;
Expert Rev Neurother; 2011 May; 11(5):657-63. PubMed ID: 21539486
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
3. [Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study)].
Gil-Néciga E; Gobartt AL;
Rev Neurol; 2008 Apr 16-30; 46(8):461-4. PubMed ID: 18428102
[TBL] [Abstract][Full Text] [Related]
4. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
[TBL] [Abstract][Full Text] [Related]
5. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M
Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422
[TBL] [Abstract][Full Text] [Related]
6. [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].
González-Gutiérrez JL; Gobartt AL;
Rev Neurol; 2007 Jun 16-30; 44(12):705-10. PubMed ID: 17583861
[TBL] [Abstract][Full Text] [Related]
7. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
8. Differences in diagnostic process, treatment and social Support for Alzheimer's dementia between primary and specialist care: resultss from the Swedish Dementia Registry.
Garcia-Ptacek S; Modéer IN; Kåreholt I; Fereshtehnejad SM; Farahmand B; Religa D; Eriksdotter M
Age Ageing; 2017 Mar; 46(2):314-319. PubMed ID: 27810851
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
10. Referral patterns and diagnosis in presenile Alzheimer's disease: implications for general practice.
Newens AJ; Forster DP; Kay DW
Br J Gen Pract; 1994 Sep; 44(386):405-7. PubMed ID: 8790653
[TBL] [Abstract][Full Text] [Related]
11. Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French REAL.FR cohort.
Gillette-Guyonnet S; Cortes F; Cantet C; Vellas B;
J Nutr Health Aging; 2005; 9(2):69-73. PubMed ID: 15791348
[TBL] [Abstract][Full Text] [Related]
12. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
13. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
Borkowska A; Ziolkowska-Kochan M; Rybakowski JK
Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
[TBL] [Abstract][Full Text] [Related]
14. Practical treatment strategies for patients with Alzheimer's disease.
Christensen DD; Lin P
J Fam Pract; 2007 Dec; 56(12 Suppl New):S17-23. PubMed ID: 18664338
[TBL] [Abstract][Full Text] [Related]
15. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
[TBL] [Abstract][Full Text] [Related]
16. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
Lopez OL; Becker JT; Saxton J; Sweet RA; Klunk W; DeKosky ST
J Am Geriatr Soc; 2005 Jan; 53(1):83-7. PubMed ID: 15667381
[TBL] [Abstract][Full Text] [Related]
17. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
Jones RW; Kivipelto M; Feldman H; Sparks L; Doody R; Waters DD; Hey-Hadavi J; Breazna A; Schindler RJ; Ramos H;
Alzheimers Dement; 2008 Mar; 4(2):145-53. PubMed ID: 18631958
[TBL] [Abstract][Full Text] [Related]
18. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
Amuah JE; Hogan DB; Eliasziw M; Supina A; Beck P; Downey W; Maxwell CJ
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):670-9. PubMed ID: 20583207
[TBL] [Abstract][Full Text] [Related]
19. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
